Derleme
BibTex RIS Kaynak Göster

Yıl 2021, Cilt: 1 Sayı: 1, 33 - 37, 17.01.2023

Burak Bayrak Büşra Yüksel Yücel Kadıoğlu

Öz

Kaynakça

  • 1.World Health Organization. Epilepsy. 2019;20:6. Accessed 1 September 2021. Available: http://www.globalizationandhealth.com/content/1/1/14.
  • 2. Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2019;18(5):459-480.
  • 3. Fiest KM, Sauro KM, Wiebe S, Patten SB, Kwon CS, Dykeman J, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88(3):296-303.
  • 4. Bharucha NE, Bharucha EP, Bharucha AE, Bhise AV, Schoenberg BS. Prevalence of epilepsy in the Parsi community of Bombay. Epilepsia. 1988;29(2):111-5.
  • 5. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia. 1993;34(3):453-458.
  • 6. Proposal for Revised Classification of Epilepsies and Epileptic Syndromes. Commission on classification and terminology of the International League Against Epilepsy. Epilepsia. 1989;30(4):389-399.
  • 7. Hampel KG, Garcés Sánchez M, Gómez Ibañez A, Palanca-Cámara M, Villanueva V. Desafíos diagnósticos en epilepsia. Rev Neurol. 2019;68(6):255-263.
  • 8. Leach, J. Lauder R.. Nicolson A. Smith D. Epilepsy in the UK: Misdiagnosis, mistreatment, and undertreatment?: The Wrexham area epilepsy project. Seizure. 2005;14(7):514-520.
  • 9. Villanueva, V. Sanchez-Alvarez J.. Pena P. Salas-Puig J. Caballero-Martinez F. Gil-Nagel A. Treatment initiation in epilepsy: an expert consensus in Spain. Epilepsy & Behavior. 2010;19(3):332-342.
  • 10. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482.
  • 11. Meinardi H, Scott R, Reis JS. On Behalf Of The Ilae Commission on the Developing World. The treatment gap in epilepsy: the current situation and ways forward. Epilepsia. 2001;42(1):136-149.
  • 12. Meyer, A, Dua CT, Ma J, Saxena S, Birbeck G. Global disparities in the epilepsy treatment gap: a systematic review. Bulletin of the World Health Organization. 2010;88:260-266.
  • 13. St Louis EK, Rosenfeld WE, Bramley T. Antiepileptic drug monotherapy: the initial approach in epilepsy management. Current neuropharmacology. 2009;7(2):77-82.
  • 14. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's the pharmacological basis of therapeutics. 2018: McGraw-Hill Education New York.
  • 15. Liu G, Slater N, Perkins A. Epilepsy: treatment options. American family physician. 2017;96(2):87-96.
  • 16. Vajda FJ, Hitchcock A, Graham J, O'Brien T, Lander C, Eadie M. Seizure control in antiepileptic drug‐treated pregnancy. Epilepsia. 2008;49(1):172-176.
  • 17. Canger R, Battino D, Canevini MP, Fumarola C, Guidolin L, Vignoli A, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia. 1999;40(9):1231-6.
  • 18. MacDonald SC, Bateman BT, McElrath TF, Hernández-Díaz S. Mortality and morbidity during delivery hospitalization among pregnant women with epilepsy in the United States. JAMA neurology. 2015;72(9):981-988.
  • 19. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery & Psychiatry. 2006;77(2):193-198.
  • 20. Moore JL, Aggarwal P. Lamotrigine use in pregnancy. Expert opinion on pharmacotherapy. 2012;13(8):1213-1216.
  • 21. Holmes LB, Hernandez‐Diaz S. Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Research Part A: Clinical and Molecular Teratology. 2012;94(8):599-606.
  • 22. Group ES. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology. 2006;66(3):354-360.

A Review on Epilepsy and Planned Pregnancy in Patients with Epilepsy

Yıl 2021, Cilt: 1 Sayı: 1, 33 - 37, 17.01.2023

Burak Bayrak Büşra Yüksel Yücel Kadıoğlu

Öz

The number of patients with epilepsy varies regionally around the world, but it is one of the most common neurological diseases. The treatment and diagnosis of epilepsy is a complex condition. The term "resolved" is used in the treatment of epilepsy. When theepilepsy is resolved, it means that the person no longer has epilepsy, but it does not guarantee that it will not return. When the disease reaches certain ages, it can improvewithout treatment. In patients with epilepsy, pregnancy is possible, but the treatment to be applied in terms of maternal and child health should be chosen correctly. If reliable drugs are chosen in terms of teratogenicity in the treatment of epilepsy in pregnancy and pregnancy is planned, patients can become mothers with confidence. In this review, information about epilepsy disease, historical prevalence of the disease and drugs that are safe to use in patients with epilepsy are given.

Anahtar Kelimeler

Antiepileptic drugs epilepsy pregnancy

Kaynakça

  • 1.World Health Organization. Epilepsy. 2019;20:6. Accessed 1 September 2021. Available: http://www.globalizationandhealth.com/content/1/1/14.
  • 2. Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2019;18(5):459-480.
  • 3. Fiest KM, Sauro KM, Wiebe S, Patten SB, Kwon CS, Dykeman J, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88(3):296-303.
  • 4. Bharucha NE, Bharucha EP, Bharucha AE, Bhise AV, Schoenberg BS. Prevalence of epilepsy in the Parsi community of Bombay. Epilepsia. 1988;29(2):111-5.
  • 5. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia. 1993;34(3):453-458.
  • 6. Proposal for Revised Classification of Epilepsies and Epileptic Syndromes. Commission on classification and terminology of the International League Against Epilepsy. Epilepsia. 1989;30(4):389-399.
  • 7. Hampel KG, Garcés Sánchez M, Gómez Ibañez A, Palanca-Cámara M, Villanueva V. Desafíos diagnósticos en epilepsia. Rev Neurol. 2019;68(6):255-263.
  • 8. Leach, J. Lauder R.. Nicolson A. Smith D. Epilepsy in the UK: Misdiagnosis, mistreatment, and undertreatment?: The Wrexham area epilepsy project. Seizure. 2005;14(7):514-520.
  • 9. Villanueva, V. Sanchez-Alvarez J.. Pena P. Salas-Puig J. Caballero-Martinez F. Gil-Nagel A. Treatment initiation in epilepsy: an expert consensus in Spain. Epilepsy & Behavior. 2010;19(3):332-342.
  • 10. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482.
  • 11. Meinardi H, Scott R, Reis JS. On Behalf Of The Ilae Commission on the Developing World. The treatment gap in epilepsy: the current situation and ways forward. Epilepsia. 2001;42(1):136-149.
  • 12. Meyer, A, Dua CT, Ma J, Saxena S, Birbeck G. Global disparities in the epilepsy treatment gap: a systematic review. Bulletin of the World Health Organization. 2010;88:260-266.
  • 13. St Louis EK, Rosenfeld WE, Bramley T. Antiepileptic drug monotherapy: the initial approach in epilepsy management. Current neuropharmacology. 2009;7(2):77-82.
  • 14. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's the pharmacological basis of therapeutics. 2018: McGraw-Hill Education New York.
  • 15. Liu G, Slater N, Perkins A. Epilepsy: treatment options. American family physician. 2017;96(2):87-96.
  • 16. Vajda FJ, Hitchcock A, Graham J, O'Brien T, Lander C, Eadie M. Seizure control in antiepileptic drug‐treated pregnancy. Epilepsia. 2008;49(1):172-176.
  • 17. Canger R, Battino D, Canevini MP, Fumarola C, Guidolin L, Vignoli A, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia. 1999;40(9):1231-6.
  • 18. MacDonald SC, Bateman BT, McElrath TF, Hernández-Díaz S. Mortality and morbidity during delivery hospitalization among pregnant women with epilepsy in the United States. JAMA neurology. 2015;72(9):981-988.
  • 19. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery & Psychiatry. 2006;77(2):193-198.
  • 20. Moore JL, Aggarwal P. Lamotrigine use in pregnancy. Expert opinion on pharmacotherapy. 2012;13(8):1213-1216.
  • 21. Holmes LB, Hernandez‐Diaz S. Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Research Part A: Clinical and Molecular Teratology. 2012;94(8):599-606.
  • 22. Group ES. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology. 2006;66(3):354-360.
Toplam 22 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Eczacılık ve İlaç Bilimleri
Bölüm Reviews
Yazarlar

Burak Bayrak 0000-0001-6550-6916

Büşra Yüksel 0000-0003-1464-3886

Yücel Kadıoğlu 0000-0001-6590-7306

Yayımlanma Tarihi 17 Ocak 2023
Yayımlandığı Sayı Yıl 2021 Cilt: 1 Sayı: 1

Kaynak Göster

EndNote Bayrak B, Yüksel B, Kadıoğlu Y (01 Ocak 2023) A Review on Epilepsy and Planned Pregnancy in Patients with Epilepsy. International Journal of PharmATA 1 1 33–37.
 Kapak Resmi İndir